@AzurityPharma profile picture
Azurity Pharmaceuticals @AzurityPharma
Joined November 2012
  • Tweets 274
  • Following 287
  • Followers 380
177 Photos and videos
53
As part of our purpose to serve overlooked patients, we’re sharing that an FDA-approved ready-to-use oral solution for treating ADHD in adults and pediatric patients 6 years and older will be available mid-2026. #overlookedpatients #ADHD Learn more: bit.ly/4quaiHV
0:05
79
BREAKING NEWS: ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China hashtag #overlookedpatients azurity.com/aca-pharma-named…

ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay...

NEW YORK, NY, UNITED STATES, January 14, 2026 -- ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have entered into an exclusive distribution partnership under which ACA...

azurity.com
1
62
Even with multiple options for #hypertension, ~33M Americans still have high #bloodpressure despite treatment. Watch the @HCPLiveNews full interview with Paul Whelton, MD, here👉 bit.ly/4pmotPH
56
BREAKING NEWS: Azurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral Solution #overlookedpatients #hypertension #innovation azurity.com/azurity-pharmace…

Azurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral...

Woburn, MA—December 18, 2025—Azurity Pharmaceuticals, Inc. announced today the availability of JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-...

azurity.com
71
We're heading to Las Vegas, NV for the 2025 ASHP Midyear Clinical Meeting (December 8-10). Come visit us at Booth #654 to learn more about how Azurity is serving overlooked patients. #ASHP25 #OverlookedPatients
70
We're heading to Chicago, IL for the 2025 Radiological Society of North America annual meeting (Nov 30-Dec 4). Come visit us at Booth #3578 to learn more about how Azurity is serving overlooked patients. #RSNA25 #OverlookedPatients
35
Breaking News: Azurity Pharmaceuticals and Sebela Pharmaceuticals announced Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise. #overlookedpatients azurity.com/azurity-pharmace…

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep...

Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel...

azurity.com
66
Innovation meets impact! Azurity Pharmaceuticals is excited to announce Ogilvy Health as our new PR and Marketing Agency of Record. Read more here: bit.ly/4p5CBwc #HealthcareMarketing #PR #BrandStrategy
2
62
Come visit us at CPHI Frankfurt stand 9.2F54 to learn more about how Azurity is serving overlooked patients! #overlookedpatients #Innovation #CPHI
1
63
BREAKING NEWS: Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution #overlookedpatients #hypertension #innovation azurity.com/azurity-pharmace…

Azurity Pharmaceuticals Announces FDA Approval of JAVADINTM (clonidine hydrochloride) Oral Solution...

Woburn, MA—October 24, 2025—Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved JavadinTM (clonidine hydrochloride) oral solution, the only...

azurity.com
2
67
azurity.com/aca-pharma-named…

ACA Pharma Named Exclusive Distributor for Feraheme® in Hong Kong, Macau, Greater Bay Area,...

New York, NY — October 23, 2025— ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have signed an exclusive distribution partnership agreement for ACA Pharma to commercialize...

azurity.com
3
61
BREAKING NEWS: Azurity Pharmaceuticals Announces the FDA Approval of Ferabright™ (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain #overlookedpatients #MRI azurity.com/azurity-pharmace…

Azurity Pharmaceuticals Announces the FDA Approval of FerabrightTM (ferumoxytol injection), the...

Woburn, MA — October 17, 2025 — Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright™ (ferumoxytol injection), the first and only...

azurity.com
2
87
Load more